Similar Prevalence of Low-Abundance Drug-Resistant Variants in Treatment-Naive Patients with Genotype 1a and 1b Hepatitis C Virus Infections as Determined by Ultradeep Pyrosequencing
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Similar Prevalence of Low-Abundance Drug-Resistant Variants in Treatment-Naive Patients with Genotype 1a and 1b Hepatitis C Virus Infections as Determined by Ultradeep Pyrosequencing
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 8, Pages e105569
Publisher
Public Library of Science (PLoS)
Online
2014-08-21
DOI
10.1371/journal.pone.0105569
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders
- (2013) Edward J. Gane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy
- (2013) Pascale Trimoulet et al. ANTIVIRAL THERAPY
- Emerging Therapeutic Targets for Hepatitis C Virus Infection
- (2013) Arun B. Jesudian et al. Clinical Gastroenterology and Hepatology
- Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
- (2013) James C. Sullivan et al. CLINICAL INFECTIOUS DISEASES
- Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection
- (2013) Patrick Marcellin et al. GASTROENTEROLOGY
- JUMP-C: A randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients
- (2013) Paul J. Pockros et al. HEPATOLOGY
- A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1
- (2013) Eric Lawitz et al. JOURNAL OF HEPATOLOGY
- 1221 NO S282T MUTATION DETECTED BY DEEP SEQUENCING IN A LARGE NUMBER OF HCV PATIENTS WHO RECEIVED GS-7977 WITH RBV AND/OR GS-0938: THE QUANTUM STUDY
- (2013) E. Svarovskaia et al. JOURNAL OF HEPATOLOGY
- 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
- (2013) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir
- (2012) Lenore A. Pelosi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
- (2012) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Hepatitis C Virus (HCV) Quasispecies Dynamics upon Short-Term Dual Therapy with the HCV NS5B Nucleoside Polymerase Inhibitor Mericitabine and the NS3/4 Protease Inhibitor Danoprevir
- (2012) S. Le Pogam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications
- (2012) Ina Vandenbroucke et al. BIOTECHNIQUES
- Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir
- (2012) Fred Poordad et al. GASTROENTEROLOGY
- Efficacy of Re-treatment With TMC435 as Combination Therapy in Hepatitis C Virus–Infected Patients Following TMC435 Monotherapy
- (2012) Oliver Lenz et al. GASTROENTEROLOGY
- Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial
- (2012) Sandra De Meyer et al. HEPATOLOGY
- Hepatitis C Virus Variants with Decreased Sensitivity to Direct-Acting Antivirals (DAAs) Were Rarely Observed in DAA-Naive Patients prior to Treatment
- (2012) Doug J. Bartels et al. JOURNAL OF VIROLOGY
- Analysis of Hepatitis C Virus Intrahost Diversity across the Coding Region by Ultradeep Pyrosequencing
- (2012) M. Lauck et al. JOURNAL OF VIROLOGY
- Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
- (2012) Xiomara V. Thomas et al. PLoS One
- Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2011) I-hung Shih et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Biochemical Study of the Comparative Inhibition of Hepatitis C Virus RNA Polymerase by VX-222 and Filibuvir
- (2011) Guanghui Yi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of Resistance to the Nonnucleoside NS5B Inhibitor Filibuvir in Hepatitis C Virus-Infected Patients
- (2011) Philip J. F. Troke et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Syntheses and initial evaluation of a series of indolo-fused heterocyclic inhibitors of the polymerase enzyme (NS5B) of the hepatitis C virus
- (2011) Xiaofan Zheng et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data
- (2011) Osvaldo Zagordi et al. BMC BIOINFORMATICS
- Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing
- (2011) André Gilles et al. BMC GENOMICS
- Hepatitis C Virus Nucleotide Inhibitors PSI-352938 and PSI-353661 Exhibit a Novel Mechanism of Resistance Requiring Multiple Mutations within Replicon RNA
- (2011) A. M. Lam et al. JOURNAL OF VIROLOGY
- Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing
- (2011) Akihiro Nasu et al. PLoS One
- Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance
- (2011) M. H. Powdrill et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
- (2010) O. Lenz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients
- (2010) Sophie Le Pogam et al. JOURNAL OF INFECTIOUS DISEASES
- Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation
- (2010) Vici Varghese et al. PLoS One
- Synthesis and Biological Characterization of B-Ring Amino Analogues of Potent Benzothiadiazine Hepatitis C Virus Polymerase Inhibitors
- (2009) John T. Randolph et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479
- (2008) S. Ali et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
- (2008) Paul J. Pockros et al. HEPATOLOGY
- Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients
- (2008) S. Le Pogam et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Minority Human Immunodeficiency Virus Type 1 Variants in Antiretroviral-Naive Persons with Reverse Transcriptase Codon 215 Revertant Mutations
- (2008) Y. Mitsuya et al. JOURNAL OF VIROLOGY
- Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a
- (2008) Isabelle Moreau et al. Virology Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started